

## REMARKS

In the Office Action dated June 26, 2008, Applicants were required to elect one of the following groups of invention:

**Group I:** claims 31, 34-38 and 40-54 drawn to a method of isolating at least one anti-ligand via utilizing a library (wet bench method) and the equation of claim 38;

**Group II:** 31, 34-37 and 39-54 drawn to a method of isolating at least one anti-ligand via utilizing a library (wet bench method) and the equation of claim 39;

**Group III:** 31, 34-37 and 39-54 drawn to a method of isolating at least one anti-ligand via utilizing a library (in silico; bioinformatics method) and the equation of claim 38;

**Group IV:** 31, 34-37 and 39-54 drawn to a method of isolating at least one anti-ligand via utilizing a library (in silico; bioinformatics method) and the equation of claim 39;

**Group V:** claim 55 drawn to a method for preparing a pharmaceutical composition;

**Group VI:** claim 56 drawn to a pharmaceutical composition;

**Group VII:** claim 57, drawn to a method for preventing, treating, imaging, or diagnosing a disease;

**Group VIII:** claim 58-59, drawn to a computer readable medium comprising program code.

Applicants elect, with traverse, to prosecute the invention of Group I, claims 31, 34-38 and 40-54. Applicants believe, however, that the claims of Groups I and II should be joined as they are linked as to form a single general inventive concept. The equation of Claim 39 is derived from the equation of claim 38, therefore, there is a technical relationship between the two equations that involves corresponding technical features. Applicants believe that Groups III and IV should be recombined for the same reason.

According to the Examiner, the claims of Group I are generic to a plurality of disclosed patentably distinct species, therefore election is required. Applicants elect, with traverse, to prosecute the species of the claimed invention wherein: (i) the separation/isolation means is a “cell membrane and/or portions thereof”; and (ii) wherein the isolation of anti-ligand bound to second target ligand is performed by density centrifugation.

Applicants believe that the present application is in condition for allowance, and respectfully request that the Office pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

The Office is authorized to charge any fees that may be necessary for consideration of this paper to Kenyon & Kenyon Deposit Account No. 11-0600.

Respectfully submitted,

KENYON & KENYON

Dated: August 26, 2008

By: Carmella L. Stephens/  
Carmella L. Stephens  
Reg. No. 41,328

One Broadway  
New York, NY 10004  
(212) 908-6320 (Telephone)  
**CUSTOMER NO. 26646**